NADPH-cytochrome P450 oxidoreductase: Roles in physiology, pharmacology, and toxicology

Drug Metabolism and Disposition

Volumn 41, Issue 1, 2013, Pages 12-23

  Riddick, David S ^a   Ding, Xinxin ^b,c   Wolf, C Roland ^d,e   Porter, Todd D ^f   Pandey, Amit V ^g   Zhang, Qing Yu ^b,c   Gu, Jun ^b,c   Finn, Robert D ^d,e   Ronseaux, Sebastien ^d,e,h   McLaughlin, Lesley A ^d,e   Henderson, Colin J ^d,e   Zou, Ling ^f   Flück, Christa E ^g  

^a UNIVERSITY OF TORONTO   (Canada)

^b WADSWORTH CENTER   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f University of Kentucky   (United States)

^g UNIVERSITY OF BERN   (Switzerland)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 MC; ANTINEOPLASTIC AGENT; BETA NAPHTHOFLAVONE; CAFFEINE; CYTOCHROME B5; DEXTROMETHORPHAN; GEFITINIB; HEME OXYGENASE; MIDAZOLAM; OMEPRAZOLE; PACLITAXEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SMALL INTERFERING RNA; SQUALENE MONOOXYGENASE; TAMOXIFEN; THALIDOMIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALLELE; AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ELECTRON TRANSPORT; ENZYME ACTIVE SITE; ENZYME MECHANISM; ENZYME SPECIFICITY; GENE DELETION; HEPATOMA CELL; HUMAN; INTESTINE EPITHELIUM; LIPIDOSIS; LIVER CELL CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE GENE; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; TISSUE SPECIFICITY;

ALLELES; ANIMALS; CYTOCHROMES B5; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHARMACEUTICAL PREPARATIONS; TUMOR CELLS, CULTURED;

MUS;

EID: 84871567803     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048991     Document Type: Conference Paper

References (64)

1. Antley R and Bixler D (1975) Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 11:397-401.
2. Auchus RJ (2004) The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 15:432-438.
3. Campbell SJ, Carlotti F, Hall PA, Clark AJ, and Wolf CR (1996) Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 109:2619-2625. (Pubitemid 26388347)
4. Conroy JL, Fang C, Gu J, Zeitlin SO, Yang W, Yang J, VanAlstine MA, Nalwalk JW, Albrecht PJ, and Mazurkiewicz JE, et al. (2010) Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nat Neurosci 13:284-286.
5. Crisponi G, Porcu C, and Piu ME (1997) Antley-Bixler syndrome: case report and review of the literature. Clin Dysmorphol 6:61-68. (Pubitemid 27041727)
6. D'Agostino J, Ding X, Zhang P, Jia K, Fang C, Zhu Y, Spink DC, and Zhang QY (2012) Potential biological functions of cytochrome P450 reductase-dependent enzymes in small intestine: novel link to expression of major histocompatibility complex class II genes. J Biol Chem 287:17777-17788.
7. Dostalek M, Hardy KD, Milne GL, Morrow JD, Chen C, Gonzalez FJ, Gu J, Ding X, Johnson DA, and Johnson JA, et al. (2008) Development of oxidative stress by cytochrome P450 induction in rodents is selective for barbiturates and related to loss of pyridine nucleotide-dependent protective systems. J Biol Chem 283:17147-17157.
8. 5 reduction by NADPH-cytochrome P-450 reductase. J Biol Chem 254:8976-8981.
9. Fang C, Gu J, Xie F, Behr M, Yang W, Abel ED, and Ding X (2008) Deletion of the NADPH-cytochrome P450 reductase gene in cardiomyocytes does not protect mice against doxorubicin-mediated acute cardiac toxicity. Drug Metab Dispos 36:1722-1728.
10. Fang C and Zhang QY (2010) The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene. J Pharmacol Exp Ther 334:156-163.
11. Finn RD, McLaren AW, Carrie D, Henderson CJ, and Wolf CR (2007) Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system. J Pharmacol Exp Ther 322:40-47. (Pubitemid 46956358)
12. 5. J Biol Chem 283:31385-31393.
13. Finn RD, Henderson CJ, Scott CL, and Wolf CR (2009) Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway. Biochem J 417:43-54.
14. 5 null mouse: a new model for studying inherited skin disorders and the role of unsaturated fatty acids in normal homeostasis. Transgenic Res 20:491-502.
15. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonça BB, Fujieda K, and Miller WL (2004) Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36:228-230. (Pubitemid 38282745)
16. Flück CE, Nicolo C, and Pandey AV (2007) Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam Clin Pharmacol 21:399-410. (Pubitemid 47084036)
17. Flück CE, Mullis PE, and Pandey AV (2009) Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation. Mol Cell Endocrinol 313:17-22.
18. Flück CE, Mullis PE, and Pandey AV (2010) Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem Biophys Res Commun 401:149-153.
19. Flück CE, Mallet D, Hofer G, Samara-Boustani D, Leger J, Polak M, Morel Y, and Pandey AV (2011a) Deletion of P399-E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency. Biochem Biophys Res Commun 412:572-577.
20. Flück CE, Meyer-Böni M, Pandey AV, Kempná P, Miller WL, Schoenle EJ, and Biason-Lauber A (2011b) Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet 89:201-218.
21. Flück CE and Pandey AV (2011) Clinical and biochemical consequences of P450 oxidoreductase deficiency. Endocr Dev 20:63-79.
22. Fukami M, Nishimura G, Homma K, Nagai T, Hanaki K, Uematsu A, Ishii T, Numakura C, Sawada H, and Nakacho M, et al. (2009) Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab 94:1723-1731.
23. Gonzalez M, Sealls W, Jesch ED, Brosnan MJ, Ladunga I, Ding X, Black PN, and DiRusso CC (2011) Defining a relationship between dietary fatty acids and the cytochrome P450 system in a mouse model of fatty liver disease. Physiol Genomics 43:121-135.
24. Gu J, Cui HD, Behr M, Zhang L, Zhang QY, Yang WZ, Hinson JA, and Ding X (2005) In vivo mechanisms of tissue-selective drug toxicity: effects of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung, and nasal mucosa. Mol Pharmacol 67:623-630. (Pubitemid 40365309)
25. Gu J, Weng Y, Zhang QY, Cui HD, Behr M, Wu L, Yang WZ, Zhang L, and Ding X (2003) Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 278:25895-25901. (Pubitemid 36835351)
26. Hart SN and Zhong XB (2008) P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 4:439-452. (Pubitemid 351728517)
27. Henderson CJ, Otto DME, Carrie D, Magnuson MA, McLaren AW, Rosewell I, and Wolf CR (2003) Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278:13480-13486. (Pubitemid 36800122)
28. Huang NW, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, and Miller WL. (2005) Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76:729-749. (Pubitemid 40563096)
29. Huang N, Agrawal V, Giacomini KM, and Miller WL (2008) Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 105:1733-1738. (Pubitemid 351346583)
30. Ilan Z, Ilan R, and Cinti DL (1981) Evidence for a new physiological role of hepatic NADPH: ferricytochrome (P-450) oxidoreductase. Direct electron input to the microsomal fatty acid chain elongation system. J Biol Chem 256:10066-10072.
31. Ireland H, Kemp R, Houghton C, Howard L, Clarke AR, Sansom OJ, and Winton DJ (2004) Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of β-catenin. Gastroenterology 126:1236-1246. (Pubitemid 38552788)
32. Kalaany NY and Mangelsdorf DJ (2006) LXRs and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68:159-191.
33. Keber R, Motaln H, Wagner KD, Debeljak N, Rassoulzadegan M, Ačimovič J, Rozman D, and Horvat S (2011) Mouse knockout of the cholesterogenic cytochrome P450 lanosterol 14α-demethylase (Cyp51) resembles Antley-Bixler syndrome. J Biol Chem 286:29086-29097.
34. Kong B, Luyendyk JP, Tawfik O, and Guo GL (2009) Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 328:116-122.
35. Krone N, Reisch N, Idkowiak J, Dhir V, Ivison HE, Hughes BA, Rose IT, O'Neil DM, Vijzelaar R, and Smith MJ, et al. (2012) Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab 97:E257-E267.
36. Li L and Porter TD (2007) Hepatic cytochrome P450 reductase-null mice reveal a second microsomal reductase for squalene monooxygenase. Arch Biochem Biophys 461:76-84. (Pubitemid 46627526)
37. Lin Y, Yao Y, Liu S, Wang L, Moorthy B, Xiong D, Cheng T, Ding X, and Gu J (2012) Role of mammary epithelial and stromal P450 enzymes in the clearance and metabolic activation of 7,12-dimethylbenz[a]anthracene in mice. Toxicol Lett 212:97-105.
38. 5 profoundly affects hepatic and extrahepatic drug metabolism. Mol Pharmacol 78:269-278.
39. Miller WL (1986) Congenital adrenal hyperplasia. N Engl J Med 314:1321-1322.
40. Miller WL, Agrawal V, Sandee D, Tee MK, Huang N, Choi JH, Morrissey K, and Giacomini KM (2011) Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 336:174-179.
41. Miller WL and Auchus RJ (2011) The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 32:81-151.
42. Nicolo C, Flück CE, Mullis PE, and Pandey AV (2010) Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol Cell Endocrinol 321:245-252.
43. Otto DME, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, Adams RH, Tickle C, and Wolf CR (2003) Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 23:6103-6116. (Pubitemid 37013089)
44. Panda SP, Buntur AR, Kar R, Tang K, and Masters BS (2012) Conditional deletion of cytochrome P450 reductase in mouse bone results in Antley-Bixler syndrome-like craniofacial and bone mass defects. FASEB J 26:784.8 (abstract).
45. Pandey AV, Kempná P, Hofer G, Mullis PE, and Flück CE (2007) Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol 21:2579-2595. (Pubitemid 47529367)
46. Pandey AV, Flück CE, and Mullis PE (2010) Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase. Biochem Biophys Res Commun 400:374-378.
47. Peterson RE, Imperato-McGinley J, Gautier T, and Shackleton C (1985) Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N Engl J Med 313:1182-1191. (Pubitemid 16205335)
48. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, and Staels B (2003) Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor. Mol Endocrinol 17:259-272. (Pubitemid 36183149)
49. Porter TD, Banerjee S, Stolarczyk EI, and Zou L (2011) Suppression of cytochrome P450 reductase (POR) expression in hepatoma cells replicates the hepatic lipidosis observed in hepatic Por-null mice. Drug Metab Dispos 39:966-973.
50. Porter TD (2012) New insights into the role of cytochrome P450 reductase (POR) in microsomal redox biology. Acta Pharmaceutica Sinica B 2:100-104.
51. Reardon W, Smith A, and Honour JW, et al. (2000) Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? J Med Genet 37:26-32. (Pubitemid 30245870)
52. Shen AL, O'Leary KA, and Kasper CB (2002) Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 277:6536-6541. (Pubitemid 34968452)
53. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, and Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731-744.
54. Wang XJ, Chamberlain M, Vassieva O, Henderson CJ, and Wolf CR (2005) Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (Por) null mice. Biochem J 388:857-867. (Pubitemid 40941573)
55. Wei Y, Zhou X, Fang C, Li L, Kluetzman K, Yang W, Zhang QY, and Ding X (2010) Generation of a mouse model with a reversible hypomorphic cytochrome P450 reductase gene: utility for tissue-specific rescue of the reductase expression, and insights from a resultant mouse model with global suppression of P450 reductase expression in extrahepatic tissues. J Pharmacol Exp Ther 334: 69-77.
56. Weng Y, DiRusso CC, Reilly AA, Black PN, and Ding X (2005) Hepatic gene expression changes in mouse models with liver-specific deletion or global suppression of the NADPH-cytochrome P450 reductase gene. Mechanistic implications for the regulation of microsomal cytochrome P450 and the fatty liver phenotype. J Biol Chem 280:31686-31698. (Pubitemid 41291916)
57. Weng Y, Fang C, Turesky RJ, Behr M, Kaminsky LS, and Ding X (2007) Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. Cancer Res 67:7825-7832. (Pubitemid 47281377)
58. Wu L, Gu J, Weng Y, Kluetzman K, Swiatek P, Behr M, Zhang QY, Zhuo XL, Xie Q, and Ding X (2003) Conditional knockout of the mouse NADPH-cytochrome P450 reductase gene. Genesis 36:177-181. (Pubitemid 37087689)
59. Wu L, Gu J, and Cui HD, et al. (2005) Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 312:35-43. (Pubitemid 40096450)
60. Xia C, Panda SP, Marohnic CC, Martásek P, Masters BS, and Kim JJ (2011) Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. Proc Natl Acad Sci USA 108:13486-13491.
61. Zhang QY, Kaminsky LS, Dunbar D, Zhang J, and Ding X (2007) Role of small intestinal cytochromes P450 in the bioavailability of oral nifedipine. Drug Metab Dispos 35:1617-1623. (Pubitemid 47296056)
62. Zhang QY, Fang C, Zhang J, Dunbar D, Kaminsky L, and Ding X (2009) An intestinal epitheliumspecific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal P450s in first-pass clearance of oral nifedipine. Drug Metab Dispos 37:651-657.
63. Zhu Y, D'Agostino J, and Zhang QY (2011) Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse. Drug Metab Dispos 39:939-943.
64. Zhu Y and Zhang QY (2012) Role of intestinal cytochrome P450 enzymes in diclofenac-induced toxicity in the small intestine. J Pharmacol Exp Ther 343:362-370.